Bristol-Myers Squibb Company (BMY) stock analysis
Healthcare · Drug Manufacturers - General
From the 10-K filed 2026-02-11
How it makes money
Bristol-Myers Squibb earns $48,194 million by selling innovative biopharmaceutical medicines globally, primarily to wholesalers, distributors, and specialty pharmacies.
Bristol-Myers Squibb generates its revenues by discovering, developing, manufacturing, and marketing transformational medicines across therapeutic areas such as oncology, hematology, immunology, and cardiovascular disease. Its products are sold worldwide, with the United States representing 69% of total revenues and international markets accounting for 29%.
Revenues are driven by demand across its Growth Portfolio and key products like Eliquis, which help offset generic erosion within its Legacy Portfolio. Sales are predominantly made to wholesalers, distributors, and specialty pharmacies, and to a lesser extent to retailers, hospitals, clinics, government agencies, and directly to patients.
What protects it: the moat
Patents and proprietary research platforms protect its earnings, though management notes that market access constraints and pricing controls increasingly challenge these advantages.
Bristol-Myers Squibb relies on differentiated research platforms spanning small molecule drugs, biologics, CAR-T cell therapies, and radiopharmaceuticals to support long-term growth. These scientific capabilities and resulting product exclusivities form the foundation of its market position.
However, management asserts that increasing pressures from pharmaceutical market access and pricing controls, required rebates, and government price setting under legislation like the IRA continually threaten its profit margins and competitive protections.
What growth costs
The filing does not detail specific ongoing capital expenditure totals for maintaining plants, but outlines $2.0 billion in expected cost savings from its productivity initiative.
Bristol-Myers Squibb invests in internal research and development alongside business development activities, including acquisitions and licensing agreements such as Orbital Therapeutics and BioNTech, to expand its pipeline.
The company also undertakes restructuring and strategic productivity initiatives to streamline its enterprise operating model across R&D, manufacturing, and commercial functions, expecting to realize approximately $2.0 billion in cost savings by the end of 2027.
What could damage it
Government price-setting authorities under the IRA can cap reimbursement rates for single-source drugs, accelerating revenue erosion prior to patent expirations.
Under the IRA, government agencies can effectively set maximum fair prices for certain single-source drugs and biologics reimbursed under Medicare. This price setting applies years following FDA approval at a statutory ceiling representing a significant discount from average prices.
As the U.S. government selects additional medicines for price negotiation or price setting, mandatory discounts reduce revenues for key products before intellectual property protections expire, permanently impairing the earnings derived from those therapies.
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.